Adult head and neck rhabdomyosarcoma: radiotherapy- based treatment, outcomes, and predictors of survival

BMC Cancer

Table 4 Univariate analysis of 42 patients with adult HNRMS

Prognostic Factor	5y-LRFS (%)	P value	5y-OS (%)	P value
Age		0.601		0.926
<28 yr	82.2		41.1
≥ 28 yr	56.8		41.4
Gender		0.825		0.318
Male	71.7		34.2
Female	64.8		50.1
Histology		0.276		0.267
Embryonal	57.3		27.3
Alveolar	81.4		64.3
Primary site		0.385		0.421
Parameningeal	58.9		36.5
Non- Parameningeal	85.2		48.9
Primary tumor size		0.047		0.142
≤ 5 cm	94.7		58.0
> 5 cm	50.0		30.9
Nodal status		0.029		0.478
N0	85.0		44.0
N1	50.0		34.7
Disease status		0.908		0.205
Local-regional (M0)	69.8		45.0
Distant (M1)	Not reached		0
IRS pretreatment staging		0.766		0.205
Stage I + II	78.4		53.6
Stage III + IV	59.9		32.8
IRS postsurgical grouping		0.385		0.333
Group I + II	65.3		43.7
Group III + IV	71.9		38.3
Surgery margins		0.162		0.301
Negative (R0)	100.0		83.3
Positive (R1/2)	58.4		40.9
Responses to chemotherapy		0.922		0.692
CR + PR	55.0		25.7
SD + PD	70.5		44.3
Chemoradiotherapy types		0.770		0.896
CCRT	67.1		37.0
No-CCRT	76.2		42.9
Local treatment patterns		0.049		0.027
Surgery + RT	73.6		52.4
RT	64.2		24.5

HNRMS, head and neck rhabdomyosarcoma; Intergroup Rhabdomyosarcoma Study, IRS; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LRFS, locoregional recurrence-free survival; OS, overall survival; CCRT, concurrent chemoradiation

ISSN: 1471-2407